40914-11-2Relevant articles and documents
COVALENT TARGETING OF E3 LIGASES
-
Paragraph 0591-0592; 0626; 0700; 0746, (2020/05/19)
Disclosed herein, inter alia, are compositions and methods for targeting E3 ligases. In an aspect is a targeted protein degrader including 1) a targeted protein binder and 2) an E3 Ubiquitin ligase binder, wherein the E3 Ubiquitin ligase is human RNF4 or human RNF114. In an aspect is provided a pharmaceutical composition including a compound as described herein, including embodiments, and a pharmaceutically acceptable excipient.
Gadolinium Complex of 1,4,7,10-Tetraazacyclododecane-N,N′,N″, N'''-1,4,7-trisacetic Acid (DO3A) Conjugate of Tranexamates: A Quest for a Liver-specific Magnetic Resonance Imaging Contrast Agent
Nam, Ki-Soo,Jeong, Hyun-Jeong,Kim, Hee-Kyung,Choi, Garam,Suh, Kyung-Jin,Chang, Yongmin,Kim, Tae-Jeong
supporting information, p. 87 - 92 (2014/02/14)
The work is directed toward the synthesis of a series of DO3A conjugates of tranexamates (1c-e) and their Gd complexes (2c-e) for use as a liver-specific MRI CA. All these complexes show thermodynamic and kinetic stabilities comparable to those of structu
SUBSTITUTED HETEROCYCLIC COMPOUNDS
-
Page 28, (2008/06/13)
Disclosed are novel heterocyclic derivatives, useful for the treatment of various disease states, in particular cardiovascular diseases such as atrial and ventricular arrhythmias, intermittent claudication, Prinzmetal's (variant) angina, stable and unstable angina, exercise induced angina, congestive heart disease, and myocardial infarction. The compounds are also useful in the treatment of diabetes.